120 related articles for article (PubMed ID: 11104606)
1. E-Cadherin complex protein expression and survival in ovarian carcinoma.
Davidson B; Gotlieb WH; Ben-Baruch G; Nesland JM; Bryne M; Goldberg I; Kopolovic J; Berner A
Gynecol Oncol; 2000 Dec; 79(3):362-71. PubMed ID: 11104606
[TBL] [Abstract][Full Text] [Related]
2. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study.
Davidson B; Nesland JM; Goldberg I; Kopolovic J; Gotlieb WH; Bryne M; Ben-Baruch G; Berner A; Reich R
Gynecol Oncol; 2001 May; 81(2):166-71. PubMed ID: 11330944
[TBL] [Abstract][Full Text] [Related]
4. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R
Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
[TBL] [Abstract][Full Text] [Related]
5. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM
Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
[TBL] [Abstract][Full Text] [Related]
6. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.
Goldberg I; Davidson B; Reich R; Gotlieb WH; Ben-Baruch G; Bryne M; Berner A; Nesland JM; Kopolovic J
Clin Cancer Res; 2001 Dec; 7(12):4073-9. PubMed ID: 11751504
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors.
Marques FR; Fonsechi-Carvasan GA; De Angelo Andrade LA; Böttcher-Luiz F
Gynecol Oncol; 2004 Jul; 94(1):16-24. PubMed ID: 15262114
[TBL] [Abstract][Full Text] [Related]
11. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
12. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.
Lee CM; Lee RJ; Hammond E; Tsodikov A; Dodson M; Zempolich K; Gaffney DK
Gynecol Oncol; 2004 Apr; 93(1):209-14. PubMed ID: 15047238
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract][Full Text] [Related]
14. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.
Ang KK; Berkey BA; Tu X; Zhang HZ; Katz R; Hammond EH; Fu KK; Milas L
Cancer Res; 2002 Dec; 62(24):7350-6. PubMed ID: 12499279
[TBL] [Abstract][Full Text] [Related]
15. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
19. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma.
Ødegaard E; Staff AC; Abeler VM; Kopolovic J; Onsrud M; Lazarovici P; Davidson B
Hum Pathol; 2007 Jan; 38(1):140-6. PubMed ID: 16996570
[TBL] [Abstract][Full Text] [Related]
20. The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma.
Ødegaard E; Staff AC; Kaern J; Flørenes VA; Kopolovic J; Tropé CG; Abeler VM; Reich R; Davidson B
Gynecol Oncol; 2006 Mar; 100(3):462-8. PubMed ID: 16216317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
